**5. Conclusion**

Bioinformatics has built up itself as a basic apparatus in target revelation. In silico pharmacology paradigm is progressing and presents a rich exhibit of chances that will help with expediating the revelation of new targets, and leads to discovery of compounds with biological activities. The drug design is based on analysis of structure of fungal species complexes. Various evaluations are found using quasi in vivo assay and pharmacokinetic analysis. For example, X-ray structures of *C. albicans* CYP51 complexes with posaconazole and VT-1161, providing a molecular mechanism for the potencies of these drugs against pathogens that are intrinsically resistant to fluconazole.
